{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:35:53Z","timestamp":1777926953964,"version":"3.51.4"},"reference-count":86,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>The clinical management of hepatocellular carcinoma (HCC) has evolved significantly over the past decade. Key advances include the introduction of immune-based treatment options, which now serve as the foundation for systemic therapies. Additionally, innovations in surgical techniques, such as robotic surgery, have broadened the scope of resection to include selected patients previously deemed unsuitable due to factors like tumor location or the presence of portal hypertension. HCC downstaging has also gained recognition as a viable strategy in appropriately selected patients, demonstrating outcomes comparable to those achieved under conventional listing criteria. Consequently, the management of HCC has become increasingly complex, underscoring the critical importance of multidisciplinary collaboration and shared decision-making. In this review, we provide a concise overview of practical recommendations for HCC management, encompassing aspects such as risk stratification, early detection, diagnosis, and treatment strategies.<\/jats:p>","DOI":"10.1055\/a-2832-4720","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:57:50Z","timestamp":1774483070000},"page":"013-22","source":"Crossref","is-referenced-by-count":0,"title":["Expert Practical Recommendations for Hepatocellular Carcinoma"],"prefix":"10.1055","volume":"46","author":[{"given":"Feng","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, United States"},{"name":"NYU Langone Transplant Institute, New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Torres-Hernandez","sequence":"additional","affiliation":[{"name":"NYU Langone Transplant Institute, New York, New York, United States"},{"name":"Department of Surgery, NYU Grossman School of Medicine, New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hickey","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, NYU Grossman School of Medicine, New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Shanbhogue","sequence":"additional","affiliation":[{"name":"Department of Radiology, NYU Langone Health, New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Spencer","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, United States"},{"name":"NYU Langone Perlmutter Cancer Center, New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Halazun","sequence":"additional","affiliation":[{"name":"NYU Langone Transplant Institute, New York, New York, United States"},{"name":"Department of Surgery, NYU Grossman School of Medicine, New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, United States"},{"name":"NYU Langone Perlmutter Cancer Center, New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"e2445525","DOI":"10.1001\/jamanetworkopen.2024.45525","article-title":"Trends in hepatocellular carcinoma mortality rates in the US and projections through 2040","volume":"7","author":"S Qiu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"R Fan","year":"2020","journal-title":"J Hepatol"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"G Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"100384","DOI":"10.1016\/j.jhepr.2021.100384","article-title":"Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection","volume":"3","author":"H Innes","year":"2021","journal-title":"JHEP Rep"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.cgh.2021.02.040","article-title":"Hepatocellular carcinoma prediction models in chronic hepatitis B: a systematic review of 14 models and external validation","volume":"19","author":"S Wu","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2021.09.009","article-title":"Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States","volume":"76","author":"H S Kim","year":"2022","journal-title":"J Hepatol"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"A G Singal","year":"2023","journal-title":"Hepatology"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2022.11.003","article-title":"Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis","volume":"78","author":"P Nahon","year":"2023","journal-title":"J Hepatol"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis","volume":"77","author":"A G Singal","year":"2022","journal-title":"J Hepatol"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"B H Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis","volume":"73","author":"E Wolf","year":"2021","journal-title":"Hepatology"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"B Sangro","year":"2025","journal-title":"J Hepatol"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"K Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1055-9965.EPI-13-0870","article-title":"The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers","volume":"23","author":"P J Johnson","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.gastro.2024.09.008","article-title":"A phase 3 biomarker validation of GALAD for the detection of hepatocellular carcinoma in cirrhosis","volume":"168","author":"T L Marsh","year":"2025","journal-title":"Gastroenterology"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"e0565","DOI":"10.1097\/HC9.0000000000000565","article-title":"National Liver Cancer Screening Trial (TRACER) study protocol","volume":"8","author":"A G Singal","year":"2024","journal-title":"Hepatol Commun"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/HEP.0000000000000953","article-title":"HES V2.0 outperforms GALAD for detection of HCC: a phase 3 biomarker study in the United States","volume":"81","author":"H B El-Serag","year":"2025","journal-title":"Hepatology"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cgh.2021.08.010","article-title":"Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma","volume":"20","author":"N P Chalasani","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"ref20","first-page":"e0800","article-title":"Performance of the multi-target hepatocellular carcinoma blood test: design and rationale of the ALTUS study","volume":"9","author":"B V John","year":"2025","journal-title":"Hepatol Commun"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001589","article-title":"Late breaking abstracts","volume":"2025","year":"2025","journal-title":"Hepatology"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2021.01.041","article-title":"Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis","volume":"75","author":"P Gupta","year":"2021","journal-title":"J Hepatol"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"101666","DOI":"10.1016\/j.jhepr.2025.101666","article-title":"Practice changing RCT design and rationale: abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study)","volume":"8","author":"G N Ioannou","year":"2025","journal-title":"JHEP Rep"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2018.11.020","article-title":"Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review","volume":"156","author":"C B van der Pol","year":"2019","journal-title":"Gastroenterology"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1007\/s00330-022-08985-z","article-title":"Diagnostic performance of CT versus MRI liver imaging reporting and data system category 5 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies","volume":"32","author":"Y Y Kim","year":"2022","journal-title":"Eur Radiol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1148\/radiol.14140690","article-title":"Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis","volume":"275","author":"Y J Lee","year":"2015","journal-title":"Radiology"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"e220646","DOI":"10.1148\/radiol.220646","article-title":"Percentages of hepatocellular carcinoma in LI-RADS categories with CT and MRI: a systematic review and meta-analysis","volume":"307","author":"S Lee","year":"2023","journal-title":"Radiology"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"7883","DOI":"10.1007\/s00330-022-08826-z","article-title":"Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis","volume":"32","author":"J Pan","year":"2022","journal-title":"Eur Radiol"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"M Reig","year":"2026","journal-title":"J Hepatol"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"M Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jhep.2024.01.010","article-title":"Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal","volume":"80","author":"F Trevisani","year":"2024","journal-title":"J Hepatol"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.31187","article-title":"Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy","volume":"72","author":"A Vitale","year":"2020","journal-title":"Hepatology"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000521665","article-title":"Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial)","volume":"11","author":"T Takayama","year":"2021","journal-title":"Liver Cancer"},{"issue":"08","key":"ref34","doi-asserted-by":"crossref","first-page":"101420","DOI":"10.1016\/j.jhepr.2025.101420","article-title":"Minimally invasive hepatectomy vs. thermoablation for single small (\u22643\u2009cm) hepatocellular carcinoma: a weighted real-life national comparison","volume":"7","author":"F Giuliante","year":"2025","journal-title":"JHEP Rep"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/hep.29883","article-title":"Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies","volume":"68","author":"M H Hyun","year":"2018","journal-title":"Hepatology"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1245\/s10434-023-14376-5","article-title":"Impact of liver cirrhosis, severity of cirrhosis, and portal hypertension on the difficulty and outcomes of laparoscopic and robotic major liver resections for primary liver malignancies","volume":"31","author":"F Cipriani","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"S Qin","year":"2023","journal-title":"Lancet"},{"issue":"09","key":"ref38","first-page":"891","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity","volume":"2","author":"W J Ho","year":"2021","journal-title":"Nat Can"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/bjs\/znaa041","article-title":"Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study","volume":"108","author":"R I Troisi","year":"2021","journal-title":"Br J Surg"},{"issue":"09","key":"ref40","first-page":"779","article-title":"Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"P Tabrizian","year":"2022","journal-title":"JAMA Surg"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study","volume":"82","author":"P Tabrizian","year":"2025","journal-title":"J Hepatol"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study","volume":"24","author":"Z Guo","year":"2024","journal-title":"Am J Transplant"},{"issue":"05","key":"ref43","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/HEP.0000000000001289","article-title":"Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: an international retrospective cohort study","volume":"82","author":"B Moeckli","year":"2025","journal-title":"Hepatology"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"M S Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","article-title":"Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US multicenter HCC transplant consortium","volume":"271","author":"J DiNorcia","year":"2020","journal-title":"Ann Surg"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003520","article-title":"The role of immunotherapy prior to liver transplantation in advanced or down-staged HCC - timing of transplants, selection of patients and hurdles to overcome with immunosuppression","author":"P Tabrizian","year":"2025","journal-title":"Int J Surg"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/hep.23466","article-title":"Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis","volume":"51","author":"Y K Cho","year":"2010","journal-title":"Hepatology"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jhep.2013.04.009","article-title":"Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma","volume":"59","author":"A Cucchetti","year":"2013","journal-title":"J Hepatol"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jhep.2018.12.027","article-title":"Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients","volume":"70","author":"A Doyle","year":"2019","journal-title":"J Hepatol"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(18)30029-3","article-title":"Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial","volume":"3","author":"N Vietti Violi","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"09","key":"ref51","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jvir.2017.04.025","article-title":"Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy","volume":"28","author":"R C Gaba","year":"2017","journal-title":"J Vasc Interv Radiol"},{"issue":"17","key":"ref52","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone","volume":"34","author":"K T Brown","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9319","key":"ref53","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"J M Llovet","year":"2002","journal-title":"Lancet"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"C M Lo","year":"2002","journal-title":"Hepatology"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"J Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"R Golfieri","year":"2014","journal-title":"Br J Cancer"},{"issue":"06","key":"ref57","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","article-title":"Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis","volume":"48","author":"A Facciorusso","year":"2016","journal-title":"Dig Liver Dis"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"M Kudo","year":"2025","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"B Sangro","year":"2025","journal-title":"Lancet"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"R Salem","year":"2016","journal-title":"Gastroenterology"},{"issue":"04","key":"ref61","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jvir.2023.12.009","article-title":"Locoregional therapies for hepatocellular carcinoma prior to liver transplant: comparative pathologic necrosis, radiologic response, and recurrence","volume":"35","author":"M Mosenthal","year":"2024","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"ref62","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","article-title":"Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization","volume":"11","author":"R Salem","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","article-title":"Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants","volume":"48","author":"A Gabr","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"ref64","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1007\/s00259-022-05776-y","article-title":"Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors","volume":"49","author":"S A Montazeri","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"09","key":"ref65","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study","volume":"7","author":"E Kim","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"E Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"R J Lewandowski","year":"2018","journal-title":"Radiology"},{"issue":"06","key":"ref68","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jhep.2025.01.005","article-title":"Radiation segmentectomy for early hepatocellular carcinoma is curative","volume":"82","author":"R Salem","year":"2025","journal-title":"J Hepatol"},{"issue":"04","key":"ref69","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"A L Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"08","key":"ref70","first-page":"a2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"G K Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"04","key":"ref71","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"L Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"T Yau","year":"2025","journal-title":"Lancet"},{"issue":"04","key":"ref73","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"J M Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"Lancet"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"G K Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"J Bruix","year":"2017","journal-title":"Lancet"},{"issue":"07","key":"ref77","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"A X Zhu","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"ref78","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"J Bruix","year":"2015","journal-title":"Lancet Oncol"},{"issue":"09","key":"ref79","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.transproceed.2012.09.022","article-title":"Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation","volume":"44","author":"G C Sotiropoulos","year":"2012","journal-title":"Transplant Proc"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5152\/tjg.2020.19877","article-title":"Therapeutic efficacy of sorafenib in patients with hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis","volume":"32","author":"Z Li","year":"2021","journal-title":"Turk J Gastroenterol"},{"issue":"02","key":"ref81","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.21873\/anticanres.15581","article-title":"Efficacy and safety of lenvatinib for the treatment of recurrent hepatocellular carcinoma after living donor liver transplantation: a report of two cases","volume":"42","author":"A Ichida","year":"2022","journal-title":"Anticancer Res"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/cam4.5123","article-title":"Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation","volume":"12","author":"K Bang","year":"2023","journal-title":"Cancer Med"},{"issue":"12","key":"ref83","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/lt.26264","article-title":"Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation: a retrospective study","volume":"27","author":"M Iavarone","year":"2021","journal-title":"Liver Transpl"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/liv.15419","article-title":"Immune checkpoint inhibitors in malignancies after liver transplantation: a systematic review and pooled analysis","volume":"43","author":"S Kayali","year":"2023","journal-title":"Liver Int"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12916-025-04352-z","article-title":"Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study","volume":"23","author":"D Ma","year":"2025","journal-title":"BMC Med"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1200\/OP.20.00558","article-title":"Application of ASCO value framework to treatment advances in hepatocellular carcinoma","volume":"17","author":"E Y Chen","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"03","key":"ref87","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review","volume":"10","author":"S Cappuyns","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2832-4720.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:30:44Z","timestamp":1777674644000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2832-4720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":86,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2832-4720","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}